News - Kyowa Hakko Kirin, Fujifilm Kyowa Kirin Biologics

Filter

Popular Filters

1 to 25 of 30 results

Kyowa Hakko drops Ph II study of bardoxolone

11-11-2013

Japanese drugmaker Kyowa Hakko Kirin says it is discontinuing its Phase II clinical studies evaluating…

DiabetesKyowa Hakko KirinNephrology and HepatologyPharmaceuticalReata PharmaceuticalsResearch

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

30-10-2013

AstraZeneca has started the Phase III Windward program for benralizumab, a potential treatment for severe…

AstraZenecaEuropeKyowa Hakko KirinMedImmunePharmaceuticalResearchRespiratory and Pulmonary

ProStrakan initiates EU launch of Sancuso

30-09-2013

ProStrakan has started the European Union roll-out of its transdermal patch Sancuso for the prevention…

BiotechnologyEuropeKyowa Hakko KirinLicensingOncologyProStrakanSancuso

Kyowa Hakko establishes translation research lab in Singapore

10-09-2013

Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 41521) has established an international R&D center…

Asia-PacificKyowa Hakko KirinPharmaceuticalResearch

Kyowa Hakko Kirin collaborates with Ultragenyx on KRN23

06-09-2013

Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 4151) has entered into a collaboration and license…

BiotechnologyKRN23Kyowa Hakko KirinLicensingPharmaceuticalRare diseasesResearchUltragenyx

Japan briefs: Kyowa Kirin debuts Onglyza; Otsuka enrolls TB study, sets up new European

10-07-2013

Japanese drugmaker Kyowa Hakko Kirin (TY: 4151) revealed that it launched the type 2 diabetes drug Onglyza…

Asia-PacificdelamanidEuropeKyowa Hakko KirinMarkets & MarketingOnglyzaOtsukaPharmaceuticalResearch

Kyowa Hakko launches PD drug Nouriast and files for additional indication of fluorouracil in Japan

31-05-2013

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) say that it launched its novel Parkinson's disease drug…

Asia-PacificfluorouracilKyowa Hakko KirinMarkets & MarketingNeurologicalNouriastOncologyPharmaceuticalRegulation

Kyowa Hakko set to file for pegfilgrastim approval in Japan following strong Ph III data

28-01-2013

Mid-size Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) on Friday released positive top-line results…

Asia-PacificBiotechnologyKyowa Hakko KirinOncologypegfilgrastimPharmaceuticalRegulationResearch

Drug discovery alliances for Boehringer and Horizon Discovery; and NovAliX with Kyowa Hakko

15-01-2013

UK-based Horizon Discovery, a provider of research tools to support the development of personalized medicines,…

Boehringer IngelheimHorizon DiscoveryKyowa Hakko KirinLicensingNovAliXOncologyPharmaceuticalResearch

Fujifilm JV plans bevacizumab biosimilar; Fujifilm Diosynth Bio alliance with Piramal for ADCs

25-10-2012

Fujifilm Kyowa Kirin Biologics has that it will endeavor to develop a biosimilar version of bevacizumab,…

AvastinbevacizumabBiotechnologyFujifilm Diosynth BiotechnologiesFujifilm Kyowa Kirin BiologicsGenericsOncologyPiramal HealthcareProductionResearchRoche

Kyowa Hakko files for additional indications for Leunase

08-10-2012

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says that it has filed an application based on evidence…

Asia-PacificKyowa Hakko KirinLeunaseOncologyPharmaceuticalRegulation

ProStrakan buys GTx' US rights to breast cancer drug Fareston

02-10-2012

Scotland-based ProStrakan, a subsidiary of Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151), has acquired…

FarestonGTxKyowa Hakko KirinMarkets & MarketingOncologyOrion PharmaPharmaceuticalProStrakan

Kyowa Hakko Kirin returns rights to Busulfex to Otsuka

17-09-2012

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) has reached agreement on returning development and marketing…

BusulfexKyowa Hakko KirinLicensingOncologyOtsukaPharmaceutical

Japan's drug majors post mixed financial results

31-07-2012

Japan's leading drugmakers rolled out financial results for the first fiscal quarter of 2013, ended June…

Daiichi SankyoDainippon Sumitomo PharmaFinancialKyowa Hakko KirinPharmaceuticalTakeda Pharmaceuticals

Otsuka sells on Japanese saxagliptin rights to Kyowa Hakko

03-07-2012

Japanese drugmakers Otsuka Pharmaceutical (TYO: 4578) and Kyowa Hakko Kirin (TYO: 4151) have entered…

Asia-PacificBristol-Myers SquibbDiabetesKyowa Hakko KirinLicensingOncologyOtsukaPharmaceuticalResearchsaxagliptin

Orexo and ProStrakan reconfigure rights to Abstral

04-06-2012

Sweden's Orexo AB (STO: ORX) and Scotland-based ProStrakan, a subsidiary of Japanese drugmaker Kyowa…

AbstralGlobalKyowa Hakko KirinLicensingOncologyOrexo ABPharmaceuticalProStrakan

Kyowa Hakko debuts Poteligeo in Japan; co-promotes Minirinmelt with Ferring

29-05-2012

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says that it has launched Poteligeo (mogamulizumab)…

Asia-PacificFerring PharmaceuticalsGenito-urinaryKyowa Hakko KirinMarkets & MarketingMinirinmeltOncologyPharmaceuticalPoteligeo

1 to 25 of 30 results

Back to top